G
Gabriel Baron
Researcher at Paris Descartes University
Publications - 143
Citations - 16945
Gabriel Baron is an academic researcher from Paris Descartes University. The author has contributed to research in topics: Randomized controlled trial & Population. The author has an hindex of 52, co-authored 138 publications receiving 14898 citations. Previous affiliations of Gabriel Baron include University of Paris-Sud & Sorbonne.
Papers
More filters
Journal ArticleDOI
The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage.
B. Charbit,Laurent Mandelbrot,E. Samain,Gabriel Baron,B. Haddaoui,H Keita,Olivier Sibony,Dominique Mahieu-Caputo,M. F. Hurtaud-Roux,Marie-Geneviève Huisse,M. H. Denninger,D. De Prost +11 more
TL;DR: Findings indicate that a simple fibrinogen measurement can anticipate the risk of severe bleeding in PPH.
Journal ArticleDOI
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis.
TL;DR: Although further validation using data from new trials is still needed, it is concluded that a clinically valid, easy-to-use measure of short-term improvement in AS has been developed.
Journal ArticleDOI
Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state
Florence Tubach,Philippe Ravaud,Gabriel Baron,Bruno Falissard,Isabelle Logeart,Nicholas Bellamy,Claire Bombardier,David T. Felson,M. Hochberg,D. van der Heijde,Maxime Dougados +10 more
TL;DR: The use of PASS in clinical trials would provide more meaningful results expressed as a proportion of patients in an acceptable symptom state as well as across age, disease duration, or sex.
Journal ArticleDOI
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.
Manu Shankar-Hari,Claire L Vale,Peter J. Godolphin,David Fisher,Higgins Jpt.,Francesca Spiga,Jelena Savović,Jelena Savović,Jayne F. Tierney,Gabriel Baron,Julie Benbenishty,Lindsay R. Berry,N Broman,Alexandre Biasi Cavalcanti,R Colman,S. De Buyser,Derde Lpg.,P Domingo,S F Omar,A Fernandez-Cruz,T Feuth,F Garcia,R Garcia-Vicuna,I Gonzalez-Alvaro,Anthony C. Gordon,Richard Haynes,Olivier Hermine,Peter Horby,Nora Horick,K Kumar,B N Lambrecht,Martin J Landray,L Leal,D J Lederer,Elizabeth Lorenzi,X Mariette,N Merchante,N A Misnan,S V Mohan,M C Nivens,J Oksi,J A Perez-Molina,R Pizov,R Porcher,S Postma,R Rajasuriar,Athimalaipet V Ramanan,P Ravaud,Pankti Reid,Abraham Rutgers,A Sancho-Lopez,Todd B. Seto,S Sivapalasingam,A S Soin,Natalie Staplin,John H. Stone,Garth W. Strohbehn,J Sunden-Cullberg,J Torre-Cisneros,L W Tsai,H. van Hoogstraten,T. van Meerten,Viviane C Veiga,P E Westerweel,Srinivas Murthy,Janet V. Diaz,John C. Marshall,Sterne Jac. +67 more
TL;DR: In this article, a prospective meta-analysis of clinical trials of patients hospitalized for COVID-19, administration of IL-6 antagonists, compared with usual care or placebo, was associated with lower 28-day all-cause mortality.
Journal ArticleDOI
Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
Xavier Mariette,Philippe Ravaud,Serge Steinfeld,Gabriel Baron,Joëlle Goetz,Eric Hachulla,Bernard Combe,Xavier Puéchal,Y.L. Pennec,Bernard Sauvezie,Aleth Perdriger,Gilles Hayem,Anne Janin,Jean Sibilia +13 more
TL;DR: This randomized, double-blind, placebo-controlled study of an anti-TNF agent did not show any evidence of efficacy of infliximab in primary SS.